---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000007"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:32:21.454061+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GRI Bio receives second Nasdaq deficiency notice for bid price below $1.00

## Summary
- Nasdaq letter on Jan 5, 2024: closing bid price below $1.00 for 30 consecutive business days.
- Company has 180 days (until July 3, 2024) to regain compliance; needs $1.00 closing bid for 10 consecutive days.
- Also still non-compliant with stockholders' equity requirement; compliance plan deadline was Jan 6, 2024.
- Special meeting on Jan 19, 2024 to vote on reverse stock split as a potential cure.
- If bid price falls to $0.10 or less for 10 consecutive days, Staff will issue delisting determination.

## SEC filing metadata
- accession: 0001824293-24-000007
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000007/0001824293-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000007/val-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000007
- JSON: https://secwatch.observer/filing/0001824293-24-000007.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000007.txt

## Key facts
- Listing & Compliance Notices
  GRI Bio, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: January 5, 2024, GRI Bio, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”), indicating that the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) because the closing bid price for the Company’s common stock was less than $1.00 for the previous 30 consecutive business days. The Letter is in addition to the previously disclosed letter received on November 22, 2023 from the Staff notifying the Company tha
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000007/0001824293-24-000007-index.htm
- Listing & Compliance Notices
  GRI Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 22, 2023 from the Staff notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and annual net income of less than $500,000 maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equ
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000007/0001824293-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.